Gastric cancer articles within Nature

Featured

• Article
  23 March 2022 | Open Access

  Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

  Results in the CheckMate 649 phase 3 trial for first-line combined nivolumab and chemotherapy treatment continue to show clinically meaningful efficacy in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 24 months, with no new safety signals.

  • Kohei Shitara
  • , Jaffer A. Ajani
  •  & Yelena Y. Janjigian

• Article | 15 December 2021

  The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Interim analysis of a phase III clinical trial of HER2-positive gastric adenocarinoma shows pembrolizumab plus trastuzumab and chemotherapy improves response rates compared with trastuzumab and chemotherapy alone.

  • Yelena Y. Janjigian
  • , Akihito Kawazoe
  •  & Hyun Cheol Chung

• Article | 05 February 2020

  AQP5 enriches for stem cells and cancer origins in the distal stomach

  AQP5 is identified as a marker for pyloric stem cells in humans and mice, and stem cells in the AQP5⁺ compartment are shown to be a source of invasive gastric cancer in mouse models.

  • Si Hui Tan
  • , Yada Swathi
  •  & Nick Barker

• Article
  23 July 2014 | Open Access

  Comprehensive molecular characterization of gastric adenocarcinoma

  The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies.

  • Adam J. Bass
  • , Vesteinn Thorsson
  •  & Jia Liu